NodThera Announces Appointment of Dr. Jyothis George as Chief Medical Officer
Jyothis brings a wealth of global leadership experience in cardiometabolic drug development, regulatory strategy and medical affairs. He joins NodThera from Amgen (NASDAQ: AMGN), where he served as Global Medical Vice President, Obesity and Related Conditions, driving strategic decision making on target indications and priority patient populations, securing investment to generate differentiating evidence and leading expert engagement. His recent responsibilities included strategic planning around MariTide, Amgen's lead candidate in obesity.
Previously, Jyothis held leadership roles at Novo Nordisk (CPH: NOVO-B) and Boehringer Ingelheim, directing pivotal programs in obesity, diabetes, heart failure and chronic kidney disease. At Novo Nordisk, Jyothis was Corporate Vice President, Clinical Development, Medical Affairs and Regulatory. There he successfully delivered multiple key clinical trials across the Novo Nordisk portfolio, including major regulatory studies for several assets including semaglutide (Wegovy®) and launching impactful educational platforms such as ObesityME and the Diabetes Masters Network. At Boehringer Ingelheim, as Global Head of Clinical Development and Medical Affairs, Cardiometabolism, he led the clinical development and medical affairs teams for two blockbuster cardiometabolic assets: empagliflozin, the first diabetes treatment to gain an FDA cardiovascular mortality indication, and the DPP4 inhibitor linagliptin. During his tenure, he successfully delivered multiple global clinical trials, including serving on steering committees of six major cardiovascular outcomes trials.
Daniel Swisher, Chief Executive Officer of NodThera, said: "We are thrilled to welcome Jyothis to NodThera as our Chief Medical Officer. He brings a critical combination of deep clinical and patient insight coupled to recent global leadership in cardiometabolic drug development, shaping landmark trials and delivering regulatory success. His expertise will be invaluable to NodThera as we advance our brain-penetrant NLRP3 inflammasome inhibitors further through clinical development."
Jyothis George, M.D., Ph.D., FRCP, FACE, commented: "Joining NodThera provides an exciting opportunity to transform the treatment of diseases driven by chronic low-grade inflammation. I am inspired by the science and the team's bold vision to reimagine what's possible for patients by restoring the body's natural metabolic balance. Together with the team, I am looking forward to building on NodThera's promising clinical momentum to deliver therapies that are not only differentiated, but truly transformative for patients."
Jyothis holds an M.B.B.S. from St. John's Medical College in Bangalore, India; a Ph.D. in Neuroendocrinology from the University of Edinburgh, and is board certified in Internal Medicine, Endocrinology and Diabetes (UK). He is a Fellow of the Royal College of Physicians (Edinburgh) and the American College of Endocrinology and has authored more than 100 peer-reviewed publications. He has previously served on the boards of Amgen Technologies Ireland and Oxford Centre for Diabetes, Endocrinology and Metabolism.
For more information about NodThera please contact:
NodTheraTel: +44 (0) 1223 608130Email: info@nodthera.com
ICR Healthcare Amber Fennell, David Daley Tel: +44 (0)20 3709 5700Email: nodthera@icrhealthcare.com
About NodTheraNodThera is a leading clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases. Led by an experienced management team, NodThera is combining a deep understanding of NLRP3 inhibition, pharmaceutical neuroscience expertise and precision chemistry. Its two lead clinical candidates are oral, small molecule NLRP3 inflammasome inhibitors, which have demonstrated differentiated, potentially best-in-class clinical profiles with significant anti-inflammatory effects and high brain penetration, offering distinct opportunities to treat multiple indications. The Company is backed by top-tier investors including 5AM Ventures, Blue Owl Capital, Epidarex Capital, F-Prime Capital, Novo Holdings, Sanofi Ventures and Sofinnova Partners. NodThera is headquartered in Philadelphia, Pennsylvania, with additional operations in Cambridge, UK. Learn more at www.nodthera.com or follow the Company on LinkedIn.Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
ASML Just Quietly Booked Billions for Its EUV Machines. Is It Time to Buy the Stock?
Key Points ASML's management doesn't know for sure whether it's going to grow next year, and this unsettles investors. The company is still confident with its long-term outlook, which is what long-term investors will want to focus on. 10 stocks we like better than ASML › Many people have never heard of ASML (NASDAQ: ASML), and fewer could explain what the company does. But chances are that you're within reach of a product that ASML helped create. Modern computers, mobile devices, and even cars wouldn't be possible without one very important thing -- lithography -- and ASML dominates that market. The company's dominance in lithography -- which I'll explain momentarily -- has led to good returns for shareholders over the last decade. ASML stock is up more than 600% during this time, compared to a 200% return for the S&P 500. However, while long-term returns have been stellar, the company's recent returns haven't been so hot. On July 16, ASML reported financial results for its second quarter of 2025, and the stock dropped about 8% in a day. In short, investors didn't like something they heard. Referring to its potential growth in 2026, CEO Christophe Fouquet said, "We cannot confirm it at this stage," due to all of the macro-economic uncertainty. That's all it took to spook investors. However, there's something that ASML investors appear to be overlooking: The company quietly just booked billions for its extreme ultraviolet (EUV) lithography machines. And that's hugely important context when thinking about ASML's future. ASML is still booking billions In the semiconductor space, everything is getting smaller and more complex, which leads to the need for more complex machines. That's where ASML comes in. It makes advanced lithography machines that have a near monopoly in the market. Companies making microchips need ASML's machines. There are a variety of ASML machines that use different processes, but the best-selling line is its EUV machines, which accounted for 48% of Q2 net system sales. The extreme ultraviolet light's wavelength is short enough to work on the world's smallest chips. ASML's Q2 numbers looked good. Q2 net sales of 7.7 billion euros were above expectations. And earnings per share (EPS) of 5.9 euros were also higher than expected. Both of these outperformances were relatively modest. By contrast, analysts only expected ASML's net bookings to be around 4.2 billion euros, whereas it reported Q2 net bookings of 5.5 billion euros -- a roughly a 30% beat. (Bookings are when the company receives an order in writing. By comparison, net sales refers to when a machine is delivered or installed.) Keep in mind that a single EUV machine from ASML can cost around $280 million, so it doesn't take too many surprise orders to swing bookings in a big way. Still, the 30% outperformance does suggest ongoing health in the semiconductor manufacturing space. So what's the problem? Semiconductor manufacturers are almost guaranteed to spend significant money in the coming years as trends such as artificial intelligence (AI), driverless cars, and renewable energy will drive demand more than ever. Manufacturers will need to spend on equipment to increase supply. It's not so much a question of "if" as "when." However, capital expenditures could be delayed because executives are waiting until uncertainty dies down. With ever-changing tariffs, companies can't predict what expenses will be. It's better to wait for the dust to settle, if possible. This is what Fouquet was referring to with his prediction for ASML's business in 2026. Its products still dominate the market, and its customers will still need them. But will they buy in 2026 or later? That's what management is unsure of and why the stock dipped. This could be an opportunity for investors who take a longer-term view on ASML stock. As the chart below shows, the stock's price-to-earnings ratio (P/E) of 31 is well below its 10-year average valuation. Looking ahead to 2030, ASML's outlook hasn't changed. By 2030, it believes it will generate revenue of 44 billion euros to 60 billion euros. For perspective, the company expects to generate revenue of about 32.5 billion euros this year. Assuming it hits the midpoint of its 2030 guidance, ASML will generate revenue of 52 billion euros in five years. That's growth of 60%, which is pretty good. Factoring in the company's dividend and stock buyback program, ASML stock could be a market-beating investment. The good thing for investors considering ASML stock today is its safety. Granted, it's possible for another company to develop a machine that makes ASML's own obsolete -- anything is possible. But ASML is considered to be well ahead of the competition in an important market, which gives its business strong profits margins. This has helped to create a strong balance sheet. In conclusion, I think ASML stock is unlikely to lose money for investors over the next five years. The business is too strong, and its products are too important. But the timing of orders could cause the stock to drop at times, like it has now. For long-term investors who believe in the company's 2030 outlook, these drops in stock price could be opportunistic entry points. Should you invest $1,000 in ASML right now? Before you buy stock in ASML, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and ASML wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025 Jon Quast has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ASML. The Motley Fool has a disclosure policy. ASML Just Quietly Booked Billions for Its EUV Machines. Is It Time to Buy the Stock? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
This Trillion-Dollar Artificial Intelligence (AI) Stock Could Double Your Money in 5 Years
Key Points Meta Platforms is going all-in on AI. This strategy should provide the company with significant growth opportunities. Meta Platforms' revenue, earnings, and stock price could double in the next five years. These 10 stocks could mint the next wave of millionaires › In 2021, social media company Facebook changed its name to Meta Platforms (NASDAQ: META), partly to reflect its new focus on its metaverse ambitions. Although it is still working on that project, over the past two years, Meta's work in artificial intelligence (AI) has become the company's primary focus. The tech leader is making moves, and if enough things go right, these initiatives could lead to superior returns in the next five years and beyond. Here's why Meta Platforms could potentially double investors' money by the end of 2030. Meta Platforms is sparing no expense Meta Platforms has been investing a significant amount of money in its AI ambitions. The company announced it would build AI data centers, a project it expects will cost hundreds of billions of dollars. Meta Platforms has made other strategic moves. It recently acquired Play AI, a company that generates human-like voices through AI. The financial details of the transactions were not disclosed. Elsewhere, Meta Platforms deepened its partnership with EssilorLuxottica, the company that owns RayBan and Oakley, both of which sell glasses and eyewear accessories. Meta Platforms and EssilorLuxottica have been working together for years, but the recent investment, estimated at roughly $3.5 billion, brings their partnership to a new level. Meta Platforms has also been trying to poach top AI talent from competitors, including OpenAI. How will Meta Platforms' AI investments pay off? Consider the company's AI hardware vision. CEO Mark Zuckerberg predicted that AI glasses will likely dominate the industry within the next five to 10 years. Perhaps he is being too optimistic, but it's worth pointing out that Meta's AI glasses, developed in collaboration with EssilorLuxottica, have impressive features. They can be controlled through voice command, take pictures and videos, and users can even share what they see on video calls on WhatsApp. Meta Platforms' revenue from these glasses currently makes up a tiny percentage of its total sales. However, provided Zuckerberg's vision for the future is even close to the truth, that segment could see incredible sales growth in the next five years and perhaps contribute more meaningfully to the tech leader's financial results. And that's just one example. Here's another: Meta Platforms' large language model (LLM), Llama, is available for free. That may seem counterintuitive. It certainly wasn't free for Meta Platforms to create Llama. However, the company aims to attract talented developers to work on and refine its LLM, ultimately (hopefully) making it the leading one on the market. Since Llama powers some of the company's AI-related initiatives, including its virtual assistant, Meta AI, this strategy could, eventually, have positive spillover effects across all these other initiatives. Revenue and earnings could double by 2030 Meta Platforms' work in AI will also help improve its advertising business, from which it currently generates the overwhelming majority of its sales. The company is looking to automate the ad creation and launch process, something that will almost certainly increase ad demand and related revenue for Meta Platforms. With an ecosystem of 3.43 billion daily active users as of the end of the first quarter, Meta Platforms' websites and apps will remain favorite targets for businesses looking to advertise to a large audience. Further, Meta Platforms has also improved engagement on its apps thanks to AI-powered recommendation algorithms. The company's business is being transformed thanks to AI, with improved productivity and more lucrative opportunities across its business. In the next five years, we could see Meta Platforms' revenue and earnings double. It almost accomplished this feat in the past half-decade. But with a laser focus on AI and multiple avenues for growth, the Facebook parent can pull it off, even with some potential headwinds, such as President Donald Trump's trade policies that have already decreased ad demand from some Asia-based companies -- not that this prevented Meta Platforms from delivering strong results in the first quarter. It's also worth mentioning that Meta Platforms now pays a dividend. Investing in the stock today while setting up automatic dividend reinvestment could lead to the kinds of returns that will more than double your initial capital by the end of 2030. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $447,134!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $40,090!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $652,133!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join , and there may not be another chance like this anytime soon.*Stock Advisor returns as of July 21, 2025 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Prosper Junior Bakiny has positions in Meta Platforms. The Motley Fool has positions in and recommends Meta Platforms. The Motley Fool has a disclosure policy. This Trillion-Dollar Artificial Intelligence (AI) Stock Could Double Your Money in 5 Years was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Green Dot to Announce Second Quarter 2025 Results on August 11th
PROVO, Utah, July 22, 2025--(BUSINESS WIRE)--Green Dot Corporation (NYSE: GDOT) will host a conference call and earnings webcast to discuss second quarter 2025 financial results on Monday, August 11th, 2025 at 5:00 p.m. ET. A press release with the company's second quarter 2025 financial results will be issued after the market closes on the same day. The live webcast of the call can be accessed from Green Dot's investor relations website at A replay will be available at the same website following the call. About Green Dot Green Dot Corporation (NYSE: GDOT) is a financial technology platform and registered bank holding company that builds banking and payment solutions to create value, retain and reward customers, and accelerate growth for businesses of all sizes. For more than two decades, Green Dot has delivered financial tools and services that address the most pressing financial needs of consumers and businesses, and that transform the way people and businesses manage and move money Green Dot delivers a broad spectrum of financial products to consumers and businesses through its portfolio of brands, including: GO2bank, a leading digital and mobile bank account offering simple, secure and useful banking for Americans living paycheck to paycheck; the Green Dot Network ("GDN") of more than 95,000 retail distribution and cash access locations nationwide; Arc by Green Dot, the single-source embedded finance platform combining all of Green Dot's secure banking and money processing capabilities to power businesses at all stages of growth; rapid! wage and disbursements solutions, providing pay card and earned wage access services to more than 6,000 businesses and their employees; and Santa Barbara TPG ("SBTPG"), the company's tax division, which processes approximately 14 million tax refunds annually. Founded in 1999, Green Dot has managed more than 80 million accounts to date both directly and through its partners. Green Dot Bank is a subsidiary of Green Dot Corporation and member of the FDIC. For more information about Green Dot's products and services, please visit View source version on Contacts Investor Relations Contact IR@ Media Contact PR@ Sign in to access your portfolio
